Arqit Quantum Inc vs Cytokinetics Inc — how do they compare? Arqit Quantum Inc trades at $23.67 (market cap $424.79M), while Cytokinetics Inc trades at $77.71 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 25× Arqit Quantum Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | CYTK | |
|---|---|---|
Market Cap | $424.79M | $10.63B |
Sector | Technology | Technology |
52-Week High | $58.27 | $87.26 |
52-Week Low | $11.78 | $34.31 |
Enterprise Value | $398.10M | $10.74B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Trailing returns across standard periods
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →